Stephen Goodman, Co-Chair of Pryor Cashman's Life Sciences Group and co-founder of Mid Atlantic Bio Angels (MABA), was quoted in the press announcing the winners of MABA's 1st Pitch Life Science competition, which was held on May 25, 2017 at Rockefeller University in New York City.
Philadelphia-based Recensa Therapeutics, which is developing a topical psoriasis treatment designed to reduce oxidative stress, nabbed the top honor of "Best in Show," and was also named "Most Fundable" by the event's investor panel.
"Recensa offered a well-structured pitch, describing a clear medical need, the limitations of existing treatments and the distinct advantages of their product," Goodman said. "I would expect that with some refinement of the pitch, the company will likely garner investor interest."
Recensa's President, Matt Handel, enthused, "We are honored to be chosen as winner of both 'Best in Show' and 'Most Fundable.' Recensa's co-founder, Dr. Oscar Perez, and I are dedicated to improving the lives of patients with psoriasis by developing the first topical pharmaceutical to target oxidative stress in this disease. We are gratified that the panel validated our approach. We will now use the excellent questions and comments from the audience and the insightful feedback from the experts to improve our communications and development plan."
To read more about the 2017 1st Pitch Life Science competition, view the full press announcement.
More About 1st Pitch Life Science
Each year, MABA invites early stage life sciences and healthcare companies to present before a panel of experienced life science investors and consultants, followed by a short audience Q&A. Presenters at 1st Pitch then have the unique benefit of hearing first-hand from the panel as they offer a constructive critique of their business model and perceived viability in the market.
Pryor Cashman's Life Sciences Practice
Our Life Sciences attorneys actively nurture entrepreneurs from the onset of their new ventures, advising on how best to structure their businesses and implement choices, acquiring rights to core technologies and connecting them with potential funding sources such as angel investors, institutional investors, and biotech and health care company venture arms.
We shepherd our clients through transactions, ensuring their critical innovations are protected, and help them secure the best minds and scientific talent to bring their technologies to the global market.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
